DAY 29:
There was no noticeable difference in SARS-COV-2 clearance time between
the Molnupiravir group and the placebo group. (WMD: 0.74; 95% CI;
[0.39, 3.14] p=0.62; I²=0%) (P-value for subgroup differences
= 0.87). (Fig 3B)
Overall: No significant outcome observed for pooled
analysis of 400mg dose of molnupiravir (WMD: 0.81; 95% CI; [0.45,
1.45] p=0.45; I²=026%).